Newcelx Ltd. current report, Q4 FY2022

Vollständiges Dokument

Filing Summary

Registrant: NLS Pharmaceutics Ltd. The request metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd. as the registrant.

Reporting period: Form 6-K for December 2022, Report No. 4, filed December 13, 2022. The filing reports a corporate and share-capital amendment rather than periodic financial results.

Material Corporate Changes

  • On December 9, 2022, the company filed Amended and Restated Articles of Association with the commercial registry of the Canton of Zurich, Switzerland.
  • Outstanding share capital increased to CHF 648,577.86, divided into 32,428,893 registered shares.
  • Authorized share capital was decreased, permitting a maximum increase of CHF 231,920.42 through the issuance of up to 11,596,021 additional registered shares.
  • The amended Articles were filed as Exhibit 99.1 and incorporated by reference into the company’s Form F-3 registration statements, File Nos. 333-268690 and 333-262489, to the extent not superseded by later filings.

Financial Metrics and Liquidity

The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other periodic financial metrics.

Guidance, Outlook, Risks and Unusual Items

  • No financial guidance, outlook, management discussion, contingencies, or operating-risk commentary is provided.
  • The principal investor-relevant item is the revised share-capital structure and the remaining authorization to issue up to 11,596,021 registered shares, which could result in future dilution if exercised.

Facts Investors Should Verify

  1. Confirm the correct issuer, as the filing identifies NLS Pharmaceutics Ltd., while the request metadata identifies Newcelx Ltd.
  2. Review Exhibit 99.1 for the complete terms of the Amended and Restated Articles of Association.
  3. Verify the current number of outstanding shares and whether any portion of the authorized issuance capacity has subsequently been used.
  4. Review later SEC filings for changes to the share-capital authorization, dilution, financing activities, or operating and financial results.